Breaking News

Vetter, MoonLake Ink Development and Mfg. Pact

Vetter will be responsible for the aseptic filling of syringes with sonelokimab, an investigational Nanobody to treat inflammatory disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on therapies for inflammatory diseases, has signed a Master Development Services Agreement with Vetter Pharma International GmbH, a global contract development and manufacturing organization for fill and finish services, ranging from development support, including clinical manufacturing, through to commercial supply.   Vetter will be responsible for the aseptic filling of syringes with sonelokimab, and the subsequen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters